188 related articles for article (PubMed ID: 34497989)
1. Apalutamide-associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy.
Tohi Y; Kataoka K; Miyai Y; Kaku Y; Dainichi T; Haba R; Tsunemori H; Sugimoto M
IJU Case Rep; 2021 Sep; 4(5):299-302. PubMed ID: 34497989
[TBL] [Abstract][Full Text] [Related]
2. Maculopapular Drug Eruption Caused by Apalutamide: Case Report and Review of the Literature.
Katayama H; Saeki H; Osada SI
J Nippon Med Sch; 2022 Nov; 89(5):550-554. PubMed ID: 34526471
[TBL] [Abstract][Full Text] [Related]
3. Apalutamide-Induced Toxic Epidermal Necrolysis in a Caucasian Patient with Metastatic Castration-Sensitive Prostate Cancer: A Case Report and Review of the Literature.
Flynn CR; Liu SC; Byrne B; Ralph J; Paz G; Anwar S; Buchalter J; Fitzpatrick OM; Markham T; Donnellan P
Case Rep Oncol; 2023; 16(1):652-661. PubMed ID: 37900799
[TBL] [Abstract][Full Text] [Related]
4. Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer.
Honda T; Tohi Y; Kaku Y; Kimura N; Kato T; Haba R; Dainichi T; Sugimoto M
IJU Case Rep; 2022 Nov; 5(6):497-500. PubMed ID: 36341202
[TBL] [Abstract][Full Text] [Related]
5. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.
Uemura H; Koroki Y; Iwaki Y; Imanaka K; Kambara T; Lopez-Gitlitz A; Smith A; Uemura H
BMC Urol; 2020 Sep; 20(1):139. PubMed ID: 32878613
[TBL] [Abstract][Full Text] [Related]
6. Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y; Kato T; Kobayashi K; Daizumoto K; Fukuhara H; Ohira S; Katayama S; Shimizu R; Takamoto A; Nishimura K; Ikeda K; Nagami T; Hayashida Y; Hirama H; Naito H; Tomida R; Sasaki Y; Yamamoto S; Shimizu S; Sugimoto M;
Jpn J Clin Oncol; 2024 Feb; 54(2):167-174. PubMed ID: 37840362
[TBL] [Abstract][Full Text] [Related]
7. Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer.
Cremante M; Puglisi S; Gandini A; Guadagno A; Catalano F; Damassi A; Murianni V; Llaja Obispo MA; Banna GL; Buti S; Rebuzzi SE; Rescigno P; Fornarini G
J Oncol Pharm Pract; 2023 Oct; 29(7):1748-1753. PubMed ID: 37282554
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease induced by apalutamide therapy for castration-resistant prostate cancer: A report of a rare case.
Kirishima F; Shigematsu Y; Kobayashi K
IJU Case Rep; 2022 May; 5(3):153-155. PubMed ID: 35509772
[TBL] [Abstract][Full Text] [Related]
9. Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Uemura H; Arai G; Uemura H; Suzuki H; Iijima K; Nishimura K; Fujii K; Hatayama T; Aoyama J; Deprince K; Lopez-Gitlitz A; McCarthy S; Larsen JS; Li J; Chi KN
Int J Urol; 2021 Mar; 28(3):280-287. PubMed ID: 33295007
[TBL] [Abstract][Full Text] [Related]
10. Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y; Kato T; Fukuhara H; Kobayashi K; Ohira S; Ikeda K; Daizumoto K; Katayama S; Shimizu R; Nishimura K; Nagami T; Hayashida Y; Hirama H; Takamoto A; Dainichi T; Sugimoto M;
Int J Clin Oncol; 2022 Aug; 27(8):1348-1355. PubMed ID: 35596089
[TBL] [Abstract][Full Text] [Related]
11. Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer.
Yang Z; Shao Y; Huang H; Liu Y; Wang Z; Wang Y
World J Urol; 2024 Mar; 42(1):171. PubMed ID: 38506974
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
Uemura H; Arai G; Uemura H; Suzuki H; Aoyama J; Hatayama T; Ito M; Lefresne F; McCarthy S; Mundle S; He J; Chi KN
Int J Urol; 2022 Jun; 29(6):533-540. PubMed ID: 35293030
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
T'jollyn H; Ackaert O; Chien C; Lopez-Gitlitz A; McCarthy S; Ruixo CP; Karsh L; Chi K; Chowdhury S; Ruixo JP; Agarwal N
Cancer Chemother Pharmacol; 2022 May; 89(5):629-641. PubMed ID: 35366072
[TBL] [Abstract][Full Text] [Related]
14. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide and Apalutamide: In Vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model.
Ji C; Guha M; Zhu X; Whritenour J; Hemkens M; Tse S; Walker GS; Evans E; Khan NK; Finkelstein MB; Callegari E; Obach RS
Chem Res Toxicol; 2020 Jan; 33(1):211-222. PubMed ID: 31538772
[TBL] [Abstract][Full Text] [Related]
16. Enzalutamide-Induced Acute Maculopapular Rash in Treatment of Metastatic Prostate Cancer: First Case Report from a Tertiary Cancer Care Center of North India.
Chakraborty A; Khanna A; Vasudeo V; Pratihar SK; Singh A; Rawal S
Indian J Surg Oncol; 2023 Sep; 14(3):571-575. PubMed ID: 37900659
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide: A new agent in the management of prostate cancer.
May MB; Glode AE
J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
[TBL] [Abstract][Full Text] [Related]
19. Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial.
Chung BH; Huang J; Ye ZQ; He DL; Uemura H; Arai G; Kim CS; Zhang YY; Koroki Y; Jeong S; Mundle S; Triantos S; McCarthy S; Chi KN; Ye DW
Asian J Androl; 2022; 24(2):161-166. PubMed ID: 34259202
[TBL] [Abstract][Full Text] [Related]
20. Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study.
Oishi T; Hatakeyama S; Tabata R; Fujimori D; Kawashima Y; Tanaka R; Ishii N; Miura H; Tanaka T; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Sato S; Ohyama C
Prostate; 2023 Feb; 83(2):198-203. PubMed ID: 36314250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]